Evidence for medical cannabis in palliative care remains inconclusive despite patient interest | Research

The takeaway

A review of medicinal cannabinoids in palliative care found strong public support but inconclusive clinical data for key symptoms like pain and nausea, with findings from other settings not easily transferable.

Read this if you or someone you care for is considering medical cannabis for palliative symptom management.

Clinical data for cannabis in palliative pain and nausea remains inconclusive

What the researchers found

The author examined the evidence base for using medicinal cannabinoids in people with palliative diagnoses, where treatments increasingly focus on symptom management earlier in the disease trajectory. Despite strong public support for cannabis availability in palliative care, the clinical evidence tells a more cautious story.

For key palliative symptoms like pain and nausea, clinical data has been inconclusive. The author specifically noted that data from chemotherapy-induced nausea and vomiting cannot be readily extrapolated to palliative care nausea, as the underlying mechanisms differ.

The review advocated for exploring medicinal cannabinoids within clinical trials to accelerate the evidence base. For patients with refractory symptoms where other treatments have failed, the author suggested that off-label prescribing should consider pharmacokinetic and pharmacodynamic interactions, drug-drug interactions, and include informed discussion with patients and regular review of whether the treatment is actually helping.

Why it matters

Palliative care patients have some of the most urgent needs for symptom relief, and many are interested in cannabis. This review provides a measured perspective that acknowledges the therapeutic potential while cautioning against assuming efficacy without adequate evidence. It bridges the gap between patient demand and clinical evidence.

The numbers in context

No specific quantitative findings reported. The review assessed the quality of evidence across multiple symptom domains in palliative care.

How the study worked

This was a narrative review and clinical commentary examining the current evidence for medicinal cannabinoids in palliative care populations, with attention to the endocannabinoid system as a therapeutic target and practical considerations for prescribing.

What this study cannot tell us

This is a narrative review and clinical commentary rather than a systematic review. The author's opinions, while informed, reflect a single expert perspective. The palliative care population is heterogeneous, and general conclusions may not apply to specific patients or conditions.

How to read the evidence

This is a narrative review reflecting expert opinion on available evidence, providing moderate-level guidance.

When this study was published

Published in 2018. Palliative cannabis research has continued with several trials since.

The bigger picture

The disconnect between strong public support for medicinal cannabis in palliative care and the actual evidence base mirrors a broader challenge in cannabis medicine. Patients facing serious illness may be more willing to try unproven treatments, making it especially important that clinicians can offer evidence-based guidance.

Questions still open

Could well-designed palliative care trials produce different results than the mixed findings from other clinical settings? What is the appropriate balance between evidence requirements and compassionate access for people with limited time? How should drug-drug interactions between cannabinoids and common palliative medications be managed?

Common questions

Does cannabis help with end-of-life symptoms?

The evidence is inconclusive. While there are areas where cannabinoids could theoretically help through the endocannabinoid system, clinical data for key palliative symptoms like pain and nausea has not shown consistent benefits. More research specifically in palliative populations is needed.

Can palliative patients try cannabis if nothing else works?

The review author suggests that for refractory symptoms, off-label cannabinoid prescribing can be considered, but should account for drug interactions, include informed patient discussion, and include regular assessment of whether it is actually providing benefit.

Read the original research

Medicinal cannabinoids in palliative care.

British journal of clinical pharmacology, 84(11), 2491-2494

View on PubMed ↗Publisher’s paper ↗

Citation

Agar, Meera. (2018). Medicinal cannabinoids in palliative care.. British journal of clinical pharmacology, 84(11), 2491-2494. https://doi.org/10.1111/bcp.13671